Recursion Pharmaceuticals
50+ PB biological database linked to drug response profiles. ClinTech initiative applies AI to clinical trial design. REC-1245 went from AI-identified target to IND in under 18 months; Phase 1 ENLYGHT study (solid tumors / SCLC) now dosing patients. Najat Khan succeeded Chris Gibson as CEO Jan 2026. Five differentiated clinical programs advancing; $500M+ in partnership milestones earned to date. $665M cash runway into early 2028.
Scenarios
Seven programs in trials is unparalleled pipeline density for this size. Exscientia merger created 30+ active programs with Roche/Bayer relationships. Single Phase 2 success re-rates entire company.
Drug discovery AI has credibility problem — multiple companies failed to translate AI candidates to clinical success. Revenue still from partnerships, cash burn continuous.
Key Factors to Watch
- ●REC-1245: target ID to IND in under 18 months — benchmark-setting; ENLYGHT Phase 1 now dosing
- ●5 programs with defined next-stage milestones; ClinTech applies AI to trial design itself
- ●Roche, Genentech, and Sanofi partnerships validate platform; $500M+ milestones earned
- ●Najat Khan as CEO (Jan 2026) — Roche/Genentech veteran, drug-development execution focus
- ●$665M cash runway into early 2028; partnership milestones are the principal revenue lever
Score History
| Date | Score | Direction | Note |
|---|---|---|---|
| 2026-03-08 | 7.6 | Positive | Score 7.5→7.6 (are 8→9, dr 2→3). External research cross-ref: entire platform is AI-driven (are up); >90% drug failure rate + program terminations (dr up) |
| 2026-03-08 | 7.5 | Positive | Initial assessment from batch 8 research |
Healthcare Peers
Last researched: 2026-05-23
This is research and analysis, not financial advice. Scores reflect AI impact potential, not investment recommendations.